Company Overview
Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. It provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. The company's solutions include Nanox Multi Source System comprising Nanox.ARC, a medical tomographic imaging system incorporating its digital X-ray source; and Nanox. CLOUD, a platform which employs a matching engine to match medical images to radiologists that provides image repository, connectivity to diagnostic assistive AI systems, billing, and reporting. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists; Nanox.CONNECT to receive local regulatory approvals and explore and evaluate the business model and the potential service; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data of existing computed tomography scans; and Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers and mobile imaging service providers, urgent care facilities, and multi-specialty physician groups. In addition, the company provides Real+ Osteoporosis Care Management Platform, a osteoporosis care management software platform; AI-Based Aortic Valve Calcification Measurement, an artificial intelligencebased solution; AI-Based Body Composition Measurement, an artificial intelligencebased body composition analysis capability; and Nanox Health IT, a healthcare information technology services provider that serves hospitals and other healthcare organizations. Nano-X Imaging Ltd. was founded in 2011 and is headquartered in Petah Tikva, Israel.
Why Investors Should Care
Net profit has compounded at 11.3% per year over the last five years.
Revenue has grown at a 14.9% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.11.
Recent Developments
- Dec 2025 Revenue of $13.02M (+15.4% YoY); net profit $-75.02M.
- Trailing 12 Months Year-on-year growth — revenue +36.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 14.9%, profit CAGR 11.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 14.93% |
| 1 Year: | 36.70% |
Compounded Profit Growth
| 5 Years: | 11.25% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -91.81% |
| 6 Months: | -78.53% |
| 3 Months: | -57.96% |
| 1 Month: | -43.65% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)19.96 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 14.9% over 5 years.
- Profit CAGR of 11.3% over 5 years.
CONS
- Trading 91.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 20 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NNOX Nano-X Imaging Ltd. R2KPHARMA | 0.37 | -0.22 | $29.08M | 0.00% | -41.78% | -98.98% | 14.93% | 11.25% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | 3.00M | 2.81M | 3.04M | 3.45M | 3.72M |
| Cost of Revenue | - | 5.89M | 5.86M | 6.28M | 6.33M | 7.34M |
| Gross Profit | - | -2.89M | -3.05M | -3.24M | -2.88M | -3.62M |
| Operating Expenses | - | 12.09M | 11.04M | 11.25M | 11.35M | 14.27M |
| Operating Income | - | -14.97M | -14.09M | -14.49M | -14.23M | -17.88M |
| EBITDA | - | -12.04M | -11.15M | -11.54M | -11.28M | -15.04M |
| Interest Expense | - | - | - | 149.00K | - | - |
| Pretax Income | - | -14.15M | -13.32M | -14.64M | -13.78M | -35.07M |
| Tax Provision | - | -94.00K | -86.00K | 82.00K | -94.00K | -1.69M |
| Net Income | - | -14.06M | -13.24M | -14.72M | -13.68M | -33.37M |
| Diluted EPS | - | -0.23 | -0.21 | -0.23 | -0.21 | -0.50 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 8.58M | 9.90M | 11.28M | 13.02M |
| Cost of Revenue | - | 15.46M | 16.50M | 21.89M | 25.81M |
| Gross Profit | - | -6.88M | -6.59M | -10.61M | -12.79M |
| Operating Expenses | - | 80.33M | 53.06M | 46.14M | 47.91M |
| Operating Income | - | -87.21M | -59.66M | -56.75M | -60.70M |
| EBITDA | - | -75.70M | -47.85M | -45.01M | -49.00M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -116.92M | -61.12M | -53.87M | -76.81M |
| Tax Provision | - | -3.68M | -339.00K | -358.00K | -1.79M |
| Net Income | - | -113.24M | -60.78M | -53.52M | -75.02M |
| Diluted EPS | - | -2.01 | -1.08 | -0.91 | -1.16 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 253.93M | 218.65M | 210.00M | 162.16M |
| Current Assets | - | 82.46M | 88.64M | 78.68M | 66.79M |
| Cash & Equivalents | - | 38.46M | 56.38M | 39.30M | 49.15M |
| Inventory | - | 0 | 2.36M | 1.49M | 3.07M |
| Receivables | - | 977.00K | 1.48M | 1.80M | 2.01M |
| Total Liabilities | - | 37.25M | 23.13M | 20.88M | 22.43M |
| Current Liabilities | - | 25.07M | 15.52M | 13.97M | 16.89M |
| Long Term Debt | 3.80M | 3.48M | - | - | - |
| Total Debt | - | 4.62M | 8.40M | 7.45M | 7.85M |
| Total Equity | - | 216.68M | 195.51M | 189.12M | 139.73M |
| Shares Outstanding | - | 55.09M | 57.78M | 63.76M | 69.59M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -43.38M | -44.78M | -36.60M | -40.79M |
| Investing Cash Flow | - | 14.61M | 35.43M | -20.05M | 29.37M |
| Financing Cash Flow | - | 804.00K | 27.25M | 39.50M | 21.37M |
| Capital Expenditure | - | -7.17M | -3.30M | -2.77M | -4.21M |
| Free Cash Flow | - | -50.56M | -48.08M | -39.37M | -45.00M |
| Net Change in Cash | - | -27.98M | 17.91M | -17.14M | 9.95M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | -80.2% | -66.6% | -94.0% | -98.2% |
| Operating Margin % | - | -1,016.6% | -602.3% | -502.9% | -466.2% |
| Net Margin % | - | -1,320.2% | -613.6% | -474.3% | -576.1% |
| ROE % | - | -52.3% | -31.1% | -28.3% | -53.7% |
| ROCE % | - | -38.1% | -29.4% | -28.9% | -41.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | UBS Group AG | 1.88% | 1.48M | $794.61K |
| 2 | ARK Investment Management, LLC | 1.03% | 806.61K | $433.80K |
| 3 | Marshall Wace LLP | 0.99% | 778.42K | $418.63K |
| 4 | Morgan Stanley | 0.83% | 654.81K | $352.15K |
| 5 | Blackrock Inc. | 0.76% | 596.03K | $320.55K |
| 6 | AQR Capital Management, LLC | 0.71% | 560.60K | $301.49K |
| 7 | Bank of America Corporation | 0.58% | 456.78K | $245.65K |
| 8 | Goldman Sachs Group Inc | 0.44% | 348.57K | $187.46K |
| 9 | HRT Financial LP | 0.42% | 330.19K | $177.58K |
| 10 | Susquehanna International Group, LLP | 0.41% | 325.31K | $174.95K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NNOX
Nano-X Imaging Ltd. (NNOX) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTFBaZHppNWxfYXNOSVJ0VGowRUU3bWY4WDVxNVdvR1pvb2xiVl9JZ3V2TGRNV1JlVUtHdEpxeXk3a21kTnl2RXZyT01mZmhicGxFRmc?oc=5" target="_blank">Nano-X Imaging Ltd. (NNOX) Stock Price, News, Quote & Hi…
Through his wholly owned company, Nano-X Imaging (NNOX) CEO buys 25,000 shares at $0.45. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOck1kZ3Y1T1lHUmVfQTFfNEt4TmdlVzdScUtwZHpKb19FY2hSSkhjYmRkNVNoWXNuYVFEbG94U2VOc3dldnhvbDRzZ0NDZGpBZEl6ZkRCWDdiOGUwMXo5czlQUy00SkxnRTJNTWlyeHhuU2xpQi1Lb2tmRnQ4bF9meVYyUi1qVVhnYmhTRU…
Nano-X Imaging (NNOX) Advances Its Mission to Expand Access to Medical Imaging - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQLTJkOHJvd0s5bnZ4TTlydy1qc3QybkhZelI5RnZJdkRmX2hUem5xV0N2T1gtQzdVYjd1Q1RQbUYyUjVQNXlaWFhrbmNhbXZzbFZMX0lUNnBvYmUtVGRZRlg1eXJxU2RNS0VHVllyaWh5UFBGM0NCM2VlUEhXZ01WcjlHX0l4SXpVdWVzak…
Nano-X stock falls on Q1 miss, going concern risk (NNOX:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxONUdSXzVIWFg1Q3lXOGkyRWIwSnBuOTlXTUFLMm11dzJFTnNKWkRXbUFhaVpTZ2pBd3pHdWZ2MlhZd2dtQ2hpUDVyV2REcHBqTUlVTEE3aEVyVlhGRWkyWklFNk15RDZucVQyZzVPRUExMy03N1NIZ0RqaFdmRVBmdVRiQ2tGWXpzYUFB?o…
Lost Money on Nano-X Imaging Ltd. (NNOX)? Join Class Action Suit Seeking Recovery - Contact SueWallSt - Morningstar
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxOZnpmb0didmJfd294QmY4QnQzS0x4ODUzMi0tVDZMbzByMU5NZWhaeEJjeEt0UnFDVTljTXpzQ3lxVWxDdTVPVjAwT0RUVjZXSGNBYWF6c0JOcGZYWkZsZzBibEhfaENaRmQ3c2xyZ1V6ajAxcTRWMFBvNkFQNVBpWk82RVV1Z243Z1JfeG…
NNOX Shareholder Alert: Nano-X Imaging Ltd. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky - PR Newswire
<a href="https://news.google.com/rss/articles/CBMijgJBVV95cUxQMWVrQTU2QUpJd2psV2dpTEhPNndxNkhIeThSV1pQdHRORXdSUmNoaVhZd1pyZ0V0YVByVWJfaWxMbExSSTNYb0xQM0pnbjk5cU12eURXUHRlRFRBS1pYM3R5U2FWR3htY2d0ZEozQzVEcjAyZ2ExdVpGMklwX3lHWGtIUUs2eExQLUg5Rn…
NNOX — Frequently Asked Questions
What is the current share price of Nano-X Imaging Ltd. (NNOX)?
As of 2026-10-23 16:27 PDT, Nano-X Imaging Ltd. (NNOX) trades at $0.37 on NasdaqGM. Its 52-week range is $0.37 to $4.55.
What is the market capitalisation of NNOX?
Nano-X Imaging Ltd. (NNOX) has a market capitalisation of $29.08M on NasdaqGM.
What is the P/E ratio of NNOX?
NNOX trades at a trailing price-to-earnings (P/E) ratio of -0.22. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 0.71.
What is the return on equity (ROE) of NNOX?
NNOX has a return on equity (ROE) of -98.98%. Its return on capital employed (ROCE) is -41.78%.
Is NNOX a good stock to buy?
This page provides a data-driven analysis of Nano-X Imaging Ltd. (NNOX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.